Skip to main content
C

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Filings indexed 730 across all filing types
Latest filing 2023-10-04 Regulatory Filings
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
CYC USFDA Approval Webinar Presentation 22 pages 2.9MB
Regulatory Filings
2023-10-04 English
SNMMI Announcement Regarding USFDA Approval of Technegas 2 pages 183.9KB
Regulatory Filings
2023-10-02 English
FDA Technegas Approval Webinar 2 pages 129.1KB
Regulatory Filings
2023-10-02 English
Cyclopharm Receives USFDA Approval for Technegas 4 pages 185.0KB
Regulatory Filings
2023-10-01 English
Cyclopharm Investor Update 21 pages 3.3MB
Regulatory Filings
2023-09-25 English
Investor Presentation Correction 22 pages 3.4MB
Regulatory Filings
2023-09-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.